Ziprasidone versus other atypical antipsychotics for schizophrenia
about
Antipsychotic medication for early episode schizophreniaCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewSimultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial DataChanges in body weight and psychotropic drugs: a systematic synthesis of the literatureLong-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials.Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general populationHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.Ziprasidone hydrocloride: what role in the management of schizophrenia?Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs).Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth.Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials.Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youthClinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with SchizophreniaEvidence review and clinical guidance for the use of ziprasidone in Canada.Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects.Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot studySystematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.
P2860
Q24236683-3EBAE58E-0DE3-4654-8A65-A733B91FFB23Q28079821-43ABC57C-12AA-49DA-A22E-6DF0A3AADDD4Q28651174-2A718783-21D7-4328-92FC-0E233354DB0AQ28728401-2135921A-A089-4427-904D-CA2FFC2E579BQ30490054-DD8F89E2-0FCD-4B0E-A235-181ADBAA8865Q33622056-C373FB8C-B3E1-49F6-86E3-892076EFA225Q34213209-6FD17D5C-3CA4-42F6-AC55-E07FB5505194Q34357931-183FD462-6609-4FF8-B60B-F7DB1F1384BEQ34620095-0D1528F7-EB1E-49E7-B361-F01B81ACD42DQ35116048-1F0143FB-060F-4620-B2D6-04F2BC15058EQ35128410-DB514A82-44DE-4037-95A2-CD244587B28CQ35256929-F8770C0B-1E0C-4008-8D1D-A5AA75B03F0BQ35572645-AB489069-692E-4D17-8D86-76143AB79B4CQ36169130-37383AAF-34B9-4723-AF1C-F2D71D97E308Q36588607-56C6A351-1538-4125-8D99-08EDF7689440Q36755212-E5C503DB-374E-4387-B74E-3709664E6432Q36848333-A2384E6A-3819-4249-BAEF-93F191B2CCECQ37060012-CC778320-B7B6-4F34-95BB-2D6B77620F95Q38473914-77203A1C-CADE-4DC9-8D44-F686B1205632Q42990103-D3A2BF65-6882-4E1C-A7A3-0AB6498BD2CD
P2860
Ziprasidone versus other atypical antipsychotics for schizophrenia
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Ziprasidone versus other atypical antipsychotics for schizophrenia
@ast
Ziprasidone versus other atypical antipsychotics for schizophrenia
@en
Ziprasidone versus other atypical antipsychotics for schizophrenia
@en-gb
Ziprasidone versus other atypical antipsychotics for schizophrenia
@nl
type
label
Ziprasidone versus other atypical antipsychotics for schizophrenia
@ast
Ziprasidone versus other atypical antipsychotics for schizophrenia
@en
Ziprasidone versus other atypical antipsychotics for schizophrenia
@en-gb
Ziprasidone versus other atypical antipsychotics for schizophrenia
@nl
prefLabel
Ziprasidone versus other atypical antipsychotics for schizophrenia
@ast
Ziprasidone versus other atypical antipsychotics for schizophrenia
@en
Ziprasidone versus other atypical antipsychotics for schizophrenia
@en-gb
Ziprasidone versus other atypical antipsychotics for schizophrenia
@nl
P2093
P2860
P50
P3181
P1476
Ziprasidone versus other atypical antipsychotics for schizophrenia
@en
P2093
Heike Hunger
Katja Komossa
Paranthaman Seth S Bhoopathi
Sandra Schwarz
P2860
P304
P3181
P356
10.1002/14651858.CD006627.PUB2
P407
P577
2009-01-01T00:00:00Z